NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Do analysts recommend NAMS or BBIO?

NewAmsterdam Pharma currently has a consensus price target of $41.30, indicating a potential upside of 87.90%. BridgeBio Pharma has a consensus price target of $61.20, indicating a potential upside of 30.94%. Given NewAmsterdam Pharma's higher probable upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
BridgeBio Pharma	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer NAMS or BBIO?

In the previous week, BridgeBio Pharma had 18 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 24 mentions for BridgeBio Pharma and 6 mentions for NewAmsterdam Pharma. BridgeBio Pharma's average media sentiment score of 0.64 beat NewAmsterdam Pharma's score of 0.64 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, NAMS or BBIO?

NewAmsterdam Pharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Which has better earnings & valuation, NAMS or BBIO?

NewAmsterdam Pharma has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$47.14M	52.35	-$241.60M	-$1.88	-11.69
BridgeBio Pharma	$221.90M	40.00	-$535.76M	-$3.53	-13.24

Is NAMS or BBIO more profitable?

NewAmsterdam Pharma has a net margin of -397.45% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-397.45%	-37.34%	-33.45%
BridgeBio Pharma	-524.25%	N/A	-94.43%

Do institutionals and insiders hold more shares of NAMS or BBIO?

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

NewAmsterdam Pharma and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.